ESMO 2023 BioNTech Data
BNT325/DB-13051 in Heavily Pretreated Patients with Multiple Solid Tumors
Phase 1/2a FIH study (NCT05438329): Baseline characteristics
Marathe O. et al. Presented at ESMO 2023. Poster #689P.
Baseline patient characteristics
Age, median (range)
Female, n (%)
Total (n=44)
59.0 (40.0-78.0)
Baseline patient characteristics
Total (n=44)
26 (59.1)
Median prior lines of therapy, median (range)
Cancer types, n (%)
3.0 (1-6)
Non-small cell lung cancer
30 (68.2)
Region, n (%)
United States
21 (47.7)
Colorectal cancer
4 (9.1)
China
23 (52.3)
HR HER2-breast cancer
2 (4.5)
ECOG performance status, n (%)
Ovarian cancer
2 (4.5)
0
1
7 (15.9)
Ampullary carcinoma
1 (2.3)
37 (84.1)
Appendiceal cancer
1 (2.3)
Duodenal cancer
1 (2.3)
Gastric or gastroesophageal junction adenocarcinoma
1 (2.3)
Primary malignant neoplasm of fallopian tube
1 (2.3)
Triple negative breast cancer
1 (2.3)
Prior anticancer systemic therapy, n (%)
With prior immunotherapy therapy
With prior platinum therapy
20 (45.5)
39 (88.6)
1. Partnered with Duality Bio..
FIH = first in human; ECOG = Eastern Cooperative Oncology Group; HR = hormone receptor; HER2 = human epidermal growth factor receptor 2;
9
BIONTECHView entire presentation